🔗 Share this article Patients Coming Off Anti-Obesity Injections Gain Back Weight Four Times Faster Compared to Those on Conventional Diets Obesity treatment involves long-term strategies. A recent study reveals that people who stop using popular slimming jabs like Wegovy and Mounjaro tend to recover shed pounds at a significantly accelerated pace than those who stop traditional diet and exercise programs. Research printed in a prominent medical journal points out that while overweight people can lose about a fifth of their body weight while using the jabs, the weight comes back at an average rate of 0.8 kg per month upon discontinuation. "Users buying these treatments should be aware of the risk of quick weight regain when the treatment concludes," stated lead investigator Dr. Susan Jebb. Such speed of recovery implies a return to original mass within about a year and a half. Analyzing Approaches The study, which reviewed 37 of studies involving thousands of participants, contrasted the results of GLP-1 agonists with conventional dieting. The team note that people who shed pounds through lifestyle changes alone usually see a less rapid creep back—around 0.1 kg a month—post-intervention. Explaining the Rapid Rebound Experts suggest the mode of action of the injections explains the accelerated regain. These medications copy a body's own chemical called glucagon-like peptide-1, which moderates hunger. "Artificially providing GLP-1 concentrations far above than the body's typical production could lead to the body to produce less of its own natural GLP-1, and could diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher. "Withdrawal of this medication means appetite is unsuppressed, making overeating far more likely." An Ongoing Disease? Medical guidelines advise the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications. A number of clinicians argue that, given the significant potential of relapse, the therapy is often life-long. This opinion is supported by drug manufacturers, who say that the findings "highlight the long-term character of obesity," comparing it to managing conditions like hypertension. Patient Testimonies Users who have stopped the jabs explain a powerful resurgence of appetite. "I experienced a switch that goes on and I was suddenly ravenous," said one woman. This difficulty is exacerbated if patients have not developed permanent lifestyle or habit modifications during therapy. Widespread Interest Survey data show that millions of people in the UK have tried these injections in the last 12 months, with demand continuing to grow. Adoption is more common among females than males. The 40s and 50s age group shows the greatest usage rates. A large proportion access the drugs through private prescriptions rather than public health services. In conclusion, clinicians emphasize that while these medications are powerful tools for shedding pounds, they are not a permanent fix and lasting health benefits hinges on combined lifestyle support.
Obesity treatment involves long-term strategies. A recent study reveals that people who stop using popular slimming jabs like Wegovy and Mounjaro tend to recover shed pounds at a significantly accelerated pace than those who stop traditional diet and exercise programs. Research printed in a prominent medical journal points out that while overweight people can lose about a fifth of their body weight while using the jabs, the weight comes back at an average rate of 0.8 kg per month upon discontinuation. "Users buying these treatments should be aware of the risk of quick weight regain when the treatment concludes," stated lead investigator Dr. Susan Jebb. Such speed of recovery implies a return to original mass within about a year and a half. Analyzing Approaches The study, which reviewed 37 of studies involving thousands of participants, contrasted the results of GLP-1 agonists with conventional dieting. The team note that people who shed pounds through lifestyle changes alone usually see a less rapid creep back—around 0.1 kg a month—post-intervention. Explaining the Rapid Rebound Experts suggest the mode of action of the injections explains the accelerated regain. These medications copy a body's own chemical called glucagon-like peptide-1, which moderates hunger. "Artificially providing GLP-1 concentrations far above than the body's typical production could lead to the body to produce less of its own natural GLP-1, and could diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher. "Withdrawal of this medication means appetite is unsuppressed, making overeating far more likely." An Ongoing Disease? Medical guidelines advise the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications. A number of clinicians argue that, given the significant potential of relapse, the therapy is often life-long. This opinion is supported by drug manufacturers, who say that the findings "highlight the long-term character of obesity," comparing it to managing conditions like hypertension. Patient Testimonies Users who have stopped the jabs explain a powerful resurgence of appetite. "I experienced a switch that goes on and I was suddenly ravenous," said one woman. This difficulty is exacerbated if patients have not developed permanent lifestyle or habit modifications during therapy. Widespread Interest Survey data show that millions of people in the UK have tried these injections in the last 12 months, with demand continuing to grow. Adoption is more common among females than males. The 40s and 50s age group shows the greatest usage rates. A large proportion access the drugs through private prescriptions rather than public health services. In conclusion, clinicians emphasize that while these medications are powerful tools for shedding pounds, they are not a permanent fix and lasting health benefits hinges on combined lifestyle support.